Related Experiment Video

Updated: May 18, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

HSP90 inhibitors for cancer therapy and overcoming drug resistance

Komal Jhaveri1, Shanu Modi

  • 1Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY, USA.

Advances in Pharmacology (San Diego, Calif.)
|September 11, 2012
PubMed

Insights

Heat shock protein 90 (HSP90) inhibitors show promise in cancer therapy, with ongoing research into their role in tumor evolution and drug resistance. Understanding HSP90 is key to developing new anticancer drugs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Heat shock protein 90 (HSP90) is a validated target for anticancer therapy.
  • Numerous first- and second-generation HSP90 inhibitors have been developed.
  • Early clinical studies show promise for HSP90 inhibitors in specific cancers.

Purpose of the Study:

  • To provide an updated overview of HSP90 inhibitor clinical development and biomarker assays.
  • To explore the role of HSP90 in tumor evolution and drug resistance.
  • To guide the optimal development of HSP90 inhibitors for regulatory approval.

Main Methods:

  • Literature review of clinical trials and preclinical studies on HSP90 inhibitors.
  • Analysis of biomarker data associated with HSP90 inhibitor therapies.
  • Synthesis of current understanding of HSP90's function in cancer progression.

Main Results:

  • Significant progress in developing potent HSP90 inhibitors.
  • Reported activity of 17-AAG in combination therapies for HER2+ breast and ALK-mutated lung cancers.
  • Identified gaps in understanding HSP90's role in resistance and evolution.

Conclusions:

  • HSP90 inhibitors represent a promising class of anticancer therapeutics.
  • Further research into HSP90's function is crucial for maximizing therapeutic potential.
  • Optimized development strategies are needed to achieve regulatory approval for HSP90 inhibitors.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology09:39

Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology

Published on: March 31, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...